Published Date: 02 Mar 2023
A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.
Read Full NewsImmune checkpoint inhibitors have been FDA-approved for head and neck cancer for a decade, but their use has only marginally increased among patients younger than 65.
As the first chemotherapy-free regimen to beat gemcitabine/cisplatin, perioperative enfortumab vedotin plus pembrolizumab could shift muscle-invasive bladder cancer care — but questions remain.
Belzutifan plus lenvatinib significantly improves outcomes vs single agent cabozantinib in patients with advanced RCC who progressed after anti-PD-(L)1 therapy, new data show.
1.
Cancer tumor anatomy influences the benefits of chemotherapy for patients with early-stage breast cancer.
2.
Aspirin Fails to Boost Survival in Colorectal Cancer Trial
3.
According to a study, breast cancer cells work together to physically breach barriers and proliferate.
4.
FDA OKs Subcutaneous Daratumumab Plus VRd for Myeloma
5.
The Kansas Cancer Center awarded two Indian American doctors professorships.
1.
The Statistical Paradigm of Leukemia: From Evolving Epidemiology and Molecular Stratification to Precision Therapies and Future Horizons in Leukemia
2.
Understanding Histiocytosis: Symptoms, Causes, and Treatment Options
3.
The Capmist DM: A Revolutionary Way to Combat Dry Mouth
4.
Understanding Neutropenic Fever: What It Is and Why it's a Serious Concern
5.
Cardio-Oncology in Survivors: Safeguarding Hearts Through Multidisciplinary Care
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part II
2.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VI
3.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
4.
Redefining Treatment Pathways in Relapsed/Refractory Adult B-Cell ALL
5.
Virtual Case Study on Elephantiasis of Lower Limb- An Initiative by Hidoc Dr.
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation